A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
You may also be interested in...
Endo still sees significant potential in Vasostrict despite the onset of competition. Meanwhile, the firm says it is focusing on “optimizing” its generics business.
The new EU regulation on increasing powers of the European Medicines Agency in future health crises applies as of 1 March; it controversially sees the agency become more involved in device oversight.
Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.